Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H1 2018

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H1 2018

Summary

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) pipeline Target constitutes close to 6 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein encoded by the TNFRSF6 gene. It acts as a receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of mature T-cells. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively.

Report covers products from therapy areas Oncology, Immunology, Ophthalmology, Central Nervous System, Dermatology and Infectious Disease which include indications Autoimmune Disorders, Retinal Pigment Epithelial (RPE) Detachment, Actinic (Solar) Keratosis, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Genital Warts (Condylomata Acuminata), Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Ovarian Cancer, Transplant Rejection, Warts and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Overview 6
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Companies Involved in Therapeutics Development 18
Baliopharm AG 18
G&E Herbal Biotechnology Co Ltd 18
KAHR medical Ltd 19
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Drug Profiles 20
APO-010 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
KAHR-102 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Novotarg - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ONL-101 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ONL-1204 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SRT-100 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Dormant Products 31
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Product Development Milestones 33
Featured News & Press Releases 33
May 31, 2017: MPIs spinout Oncology Ventures second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug 33
May 31, 2017: OVs second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug 33
Mar 28, 2017: ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team 33
Mar 21, 2017: ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program 35
Oct 07, 2016: All four Danish centers have started screening Multiple Myeloma patients for OVs APO010 Study 35
Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OVs APO010 Study 36
Mar 10, 2016: First Patient Included In APO010 Immuno-Oncology Screening Trial By MPIs Spinout Oncology Venture 36
Feb 11, 2016: ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment from FDA 37
Jun 15, 2015: ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases 37
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA 38
Dec 16, 2014: KAHR Medical receives government grant sum of 8.2 M Shekels approved by the Chief Scientist Office 38
Nov 12, 2014: ONL Therapeutics Receives Phase II SBIR Grant From National Eye Institute for Development of Novel Retinal Disease Treatment 39
Dec 24, 2013: KAHR Medical to Receive NIS 4 million (over $1.1 million USD) in Additional Government Grants 40
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 40
May 09, 2012: Baliopharm Signs Licensing Agreement For The Development Of A Bispecific Antibody Indicated For The Treatment Of Cancer And Inflammatory Diseases. 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018 7
Number of Products under Development by Therapy Areas, H1 2018 8
Number of Products under Development by Indication, H1 2018 9
Number of Products under Development by Companies, H1 2018 10
Products under Development by Companies, H1 2018 11
Number of Products by Stage and Mechanism of Actions, H1 2018 13
Number of Products by Stage and Route of Administration, H1 2018 15
Number of Products by Stage and Molecule Type, H1 2018 17
Pipeline by Baliopharm AG, H1 2018 18
Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2018 18
Pipeline by KAHR medical Ltd, H1 2018 19
Dormant Products, H1 2018 31
Dormant Products, H1 2018 (Contd..1), H1 2018 32

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018 7
Number of Products under Development by Therapy Areas, H1 2018 8
Number of Products under Development by Top 10 Indications, H1 2018 9
Number of Products by Mechanism of Actions, H1 2018 12
Number of Products by Stage and Mechanism of Actions, H1 2018 12
Number of Products by Routes of Administration, H1 2018 14
Number of Products by Stage and Routes of Administration, H1 2018 14
Number of Products by Molecule Types, H1 2018 16
Number of Products by Stage and Molecule Types, H1 2018 16

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018CD40 Ligand (T

USD 3500 View Report

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein

USD 3500 View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018CD40 Ligand (T

USD 3500 View Report

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018Tumor Necrosis Factor

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available